Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives Final Approval from the USFDA for Loperamide Hydrochloride Capsules USP, 2 mg28-03-2023
28-03-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
(1) 'Zydus receives Final Approval from the USFDA for Levothyroxine Sodium for Injection' and (2) 'Zydus receives Final Approval from the USFDA for Doxepin Hydrochloride Capsules'.28-03-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
USFDA Inspection25-03-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
The Newspaper Publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati Editions, both on March 25, 2023.25-03-2023
Zydus Lifesciences Ltd - 532321 - Closure of Trading Window
Intimation of Closure of Trading Window24-03-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives Final Approval from the USFDA for Lubiprostone Capsules, 8 mcg and 24 mcg24-03-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final Approval from the USFDA for Doxepin Hydrochloride Capsules USP, 150 mg24-03-2023
Cadila Pharma to expand and upgrade its existing facilities in Gujarat
Cadila commits 1,000-cr investment and inks MoU with Gujarat government underAtmanirbhar Gujarat Schemes for assistance to industries22-03-2023
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final and tentative Approval from the USFDA for Tofacitinib Tablets, 5 mg and 10 mg, respectively21-03-2023
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201521-03-2023